Core Insights - The research led by the team of Jin Fengyan from Jilin University First Hospital has been recognized as one of the "Top Ten Medical Researches in the Blood Field for 2025," highlighting a significant breakthrough in the clinical treatment of primary plasma cell leukemia (pPCL) [1][2] - This recognition is part of an annual evaluation by Mace Medical, which has been conducted for eight consecutive years, emphasizing the originality and impact of the selected research [1] Group 1 - The evaluation process involved selecting 15 studies from numerous submissions, which were then narrowed down to the top 10 through online voting, ensuring transparency and public engagement [1] - The research focuses on pPCL, the most aggressive subtype of multiple myeloma, which has the poorest prognosis, addressing the limitations of existing staging systems and the challenges of personalized treatment [1] - The team developed a novel pPCL-specific staging system (PSS) using real-world data from 26 centers, which incorporates easily obtainable clinical variables such as LDH, thrombocytopenia, and cytogenetic abnormalities [1] Group 2 - The PSS system breaks the constraints of current risk stratification models, providing a more accurate prediction of patient survival outcomes and serving as a critical tool for formulating targeted treatment strategies [1] - The research demonstrates the scientific strength of Jin Fengyan's team and signifies a major advancement in clinical research within the blood field in China, contributing to global pPCL diagnosis and treatment efforts [2]

来源：健康杭州 过年前，家家都忙着大扫除 62岁的赵阿姨（化名）也不例外 当她举起扫把想扫扫柜顶的灰 剧痛让她瞬间动弹不得 这一断 竟牵出了一场 潜伏在血液里的"风暴"…… 举起手扫个灰 右侧锁骨竟然当场"脆断"？ 赵阿姨平时爱干净，也很勤快，只是这大半年来，她总感到身上没力气，脸色也日益蜡黄，爬两层楼梯 就得停下喘口气。 面对家人的关心，她却说："女人老了都有点贫血，肯定是营养跟不上，多吃点桂圆红枣就好了。" 就这样，她带着这所谓的"营养不良"过了一年。直到那天大扫除，她像往常一样举起右手的扫把，去够 柜子顶上的灰尘。可刚一发力，右肩锁骨处便传来一阵钻心的剧痛，胳膊怎么也抬不起来了。 突然听到肩膀"咔嚓"一声脆响 家人赶紧把她送到急诊，X光片显示右侧锁骨骨折。与此同时，血常规结果让人心头一紧：血红蛋白仅 有58g/L，属于重度贫血。 "这不是普通的意外骨折，而是病理性骨折。"骨科医生结合贫血指标，当机立断将赵阿姨转入了杭州师 范大学附属医院血液内科。 贫血是"前哨"，骨折是"总攻" 病程其实早已启动 在血液内科病房，医生为赵阿姨安排了骨髓穿刺及相关免疫检查，结果确诊为：多发性骨髓瘤。 复盘赵阿姨的病史，其实 ...

Core Viewpoint - The incidence of multiple myeloma in China is increasing, with approximately 35,000 to 40,000 new cases diagnosed annually, primarily affecting the elderly population. Early detection and standardized treatment can lead to "functional cure" for many patients [4][7]. Group 1: Disease Overview - Multiple myeloma is a malignant blood disorder predominantly found in older adults, with a rising incidence due to aging and increased routine health check-ups [4]. - The disease progresses through three stages: Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma, and Active Myeloma, with symptoms often being non-specific and leading to misdiagnosis [5][6]. Group 2: Diagnosis and Early Detection - Approximately 60% to 70% of patients in large hospitals are misdiagnosed or undiagnosed at their first visit, highlighting the importance of early and accurate diagnosis [6]. - Regular health check-ups are crucial for early detection, especially for high-risk groups such as the elderly, those with a family history, obesity, or exposure to toxic substances [6][9]. Group 3: Treatment Advances - The median survival for multiple myeloma patients has improved from 2-3 years to 8-10 years due to advancements in treatment and the introduction of new drugs [7]. - Bispecific antibodies have shown an overall efficacy rate of 60% to 70%, providing new treatment options for relapsed/refractory patients [8]. Group 4: Multidisciplinary Collaboration - The management of multiple myeloma is evolving towards a long-term chronic disease model, necessitating multidisciplinary collaboration to address the complex health needs of patients [9]. - Comprehensive treatment plans require cooperation between various specialties, such as hematology, nephrology, and orthopedics, to ensure individualized care [9].

Core Viewpoint - The research identifies the origin cells of multiple myeloma (MM) and develops a CAR-T cell therapy targeting FCRL5, demonstrating good safety and efficacy in treating relapsed or refractory multiple myeloma (RRMM) patients [3][9]. Group 1: Research Findings - The study utilized single-cell sequencing and genetic tracing analysis to investigate each developmental stage from hematopoietic stem cells to lymphoid lineage, identifying abnormal differentiation stages in multiple myeloma patients [5]. - The research team discovered that the long arm amplification of chromosome 1 (1q Amp) originates from a specific B cell subset, while the short arm deletion of chromosome 17 (17p Del) occurs at the plasma cell stage [6]. - 1q Amp is present in the CD24- FCRL5+ B cell subset, enhancing B cell proliferation and promoting plasma cell differentiation, which initiates the transformation of B cells into malignant plasma cells [6]. Group 2: Implications for Treatment - The findings establish genetic events associated with the initiation and malignant transformation of multiple myeloma in the B cell lineage, laying the groundwork for potential treatment strategies targeting multiple myeloma initiating cells (MIC) and their driver oncogenes in RRMM patients [11].